• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

GHB, or hydroxybutyrate gamma, is a medication used for the treatment of narcolepsy. However, it has also gained controversy as a drug of misuse and has been linked to several social and legal issues. As a result, many countries have established controls to control the sale of GHB.

In the United States, GHB was listed as a Schedule I substance in 1990, which is the most restrictive classification according to US federal law. However, in 2002, GHB was rescheduled to Schedule I to Schedule III, which allowed for specific therapeutic uses, including the treatment of narcolepsy. This change in scheduling status was made due to the implementation of new formulations and the implementation of safety measures to reduce the risk of abuse.

In the Britain, GHB is classified as a Schedule B substance under the Misuse of Drugs Act 1971, which means that possessing GHB without a required license can result in penalties. Class C substances are considered to be the lesser serious of the controlled substances, but infractions involving GHB can still carry results of up to 14 years in prison.

In Canadians, ghb liquid kaufen was listed as a harsh control under the Controlled Drugs and Substances Act in 2003, which gave the Canadian government the power to regulate its use. In order to obtain GHB, Canadians typically require a license from a qualified medical practitioner, which is necessary for valid treatment of related disorders.

In Australia, GHB is classified as a most restrictive scheduling category, which is the least restrictive scheduling category under state and federal laws. This classification prohibits the transfer of GHB except for therapeutic purposes, and possession without a license can lead to severe prison sentences.

In Deutschland, GHB is classified as a Betäubungsmittel Tier 2 substance, which places it under greater restrictions than substances classified as Tier 3 but lesser restrictions than Tier 1 substances. The possession of GHB in Germany requires a permit from the regulatory authorities, and illicit use can result in penalties and imprisonment.

In the French, GHB is considered a stimulant under the Loi du 31 décembre 1970, which means that it has serious health risks, and as such is regulated and dispensed by license and license, outside therapeutic use, possible penalties of arrest as recidivists 5 years may be handed. In the Swedes, it is classified as a "strong drug" which essentially gives the same restrictive use such as drugs.

It is essential to note that the ever-shifting political and atmosphere often gives health organizations and legal regulatory commissions much to deliberate. Under such considerations GHB, often for specific purposes is discovered to be of increasingly use, and also, that many current controls can often be proven to be eventually ineffective. As existing research and findings evolve around GHB they find support supporting GHB's range in potential therapeutic uses worldwide, a dialogue ultimately that calls for continued reflection and communications in society, including strictness and alteration as appropriate legal responses.